X4 Pharmaceuticals, Inc. (XFOR) Stock Price & Analysis
X4 Pharmaceuticals, Inc. (XFOR) closed at USD 3.2 on Thursday, October 22, 2026, up 6.31% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 3.01; the Oct 22, 2026 session ranged USD 2.96–3.28 on volume of 591,782 shares. Market capitalization is $317.27M, with a 52-week range of USD 2.43–4.83 (NCM). Source: Nexqual, retrieved October 23, 2026 at 10:11 UTC.
Also available as compact Markdown for AI agents: nexqual.com/XFOR.md
Key facts (XFOR)
- Last four reported quarters (through Jun 30, 2026): revenue $15.8M, net income -$90.1M (-568.8% margin) (SEC filings).
- Analysts: Buy (mean 2.00 on a 1–5 scale) (5 analysts), mean target USD 11.6 (range 10–13).
- Total return with dividends: 1Y +3.6% vs S&P 500 +14.9%; 5Y -97.6% vs S&P 500 +80.3%.
- Next earnings: 2026-11-05, EPS estimate USD -0.19, revenue estimate $2.3M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (XFOR)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $0K | $0K | $0K | $2.6M | $35.1M | $15.8M |
| Gross profit | — | $0K | $0K | $1.8M | $29.4M | — |
| Operating income | -$85.1M | -$87.6M | -$108M | -$36.4M | -$86.9M | -$87.9M |
| Net income | -$88.7M | -$93.9M | -$101M | -$37.5M | -$79.2M | -$90.1M |
| EPS (diluted) | -$119.70 | -$45.60 | -$17.07 | -$5.59 | -$1.87 | — |
| Free cash flow | -$71.5M | -$77.2M | -$96.6M | -$131M | -$85.6M | — |
| Gross margin | — | — | — | 69.3% | 83.6% | — |
| Operating margin | — | — | — | -1400.0% | -247.4% | -554.7% |
| Net margin | — | — | — | -1440.4% | -225.6% | -568.8% |
| Revenue growth | -100.0% | — | — | — | +1250.5% | — |
| Cash + short-term investments | $81.8M | $122M | $114M | $102M | $253M | — |
| Total debt | $33.9M | $33.6M | $55.0M | $75.0M | $75.0M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (XFOR)
P/S 20.0x · EV/Sales 11.6x · P/B 2.0x · Earnings yield -28.41% · Net cash $133M · EV $184M
Analysts (XFOR)
Consensus Buy (mean 2.00 on a 1–5 scale), 5 analysts; mean target USD 11.6 (low 10, high 13).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-10 | Wells Fargo | Initiated | Overweight | $11 |
Total return (dividends reinvested) (XFOR)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +3.6% | -97.6% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +3.6% | -52.6% |
| Volatility (annualized) | 75.5% | 110.0% |
| Max drawdown | -47.5% (Jun 2026→Oct 2026) | -99.0% (Nov 2021→Jul 2025) |
XFOR analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.19 | $-0.20 | -5.8% | $2.3M | 5 |
| Next quarter (ends Dec 2026) | $-0.20 | $-0.21 | -5.9% | $2.3M | 5 |
| Current fiscal year (ends Dec 2026) | $-0.67 | $-0.76 | -11.5% | $16.0M | 5 |
| Next fiscal year (ends Dec 2027) | $-0.77 | $-0.91 | -16.0% | $11.6M | 4 |
XFOR options: expected move
Options price a move of about ±67.7% (±$2.13) by Dec 18, 2026, which includes earnings on Nov 5, 2026.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Dec 18, 2026 | 56 | 235.7% | ±67.7% |
30-day implied volatility 68.7% vs 69.2% realized over the last 30 trading days. Put/call ratio (volume) —. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 10:11 UTC)
| Price | USD 3.2 |
|---|---|
| Change | ▲ 6.31% (up) |
| Previous Close | USD 3.01 |
| Open | USD 2.99 |
| Day Range | USD 2.96 – 3.28 |
| 52-Week Range | USD 2.43 – 4.83 |
| Volume | 591,782 shares |
| Market Cap | $317.27M |
| Exchange | NCM |
Technical Analysis (XFOR)
Nexqual's technical model rates XFOR "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 10:11 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 52.84 (neutral) |
| vs SMA50 | Below (USD 3.43) |
| MACD | -0.13 (negative) |
Analyst Ratings (XFOR)
Wall Street analysts rate XFOR "Buy" based on 5 analysts, with a mean price target of USD 11.6 (range USD 10–13), per Nexqual as of October 23, 2026 at 10:11 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 11.6 |
| High Target | USD 13 |
| Low Target | USD 10 |
| Buy / Hold / Sell | 5 / 0 / 0 |
Earnings (XFOR)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.19 |
| Revenue Estimate | $2.30M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.13 vs est -0.18 ▲ beat |
| 2026-03-31 | USD -0.16 vs est -0.2 ▲ beat |
| 2025-12-31 | USD -0.22 vs est -0.35 ▲ beat |
| 2025-09-30 | USD -0.69 vs est -0.84 ▲ beat |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Financials & Fundamentals (XFOR)
| Total Revenue | $15.85M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +346.30% |
| Gross Margin | +81.51% |
| Operating Margin | -186.13% |
| Profit Margin | +0.00% |
| ROE | -113.08% |
| Debt / Equity | 0.5 |
| Current Ratio | 11.3 |
| Total Cash | $207.97M |
| Total Debt | $77.22M |
| Free Cash Flow (fiscal year ended Dec 2025, SEC 10-K) | -$85.62M (-1317.2% of revenue) |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Financial Health Score (XFOR)
Nexqual rates X4 Pharmaceuticals, Inc.'s overall financial health "Weak" across five dimensions, as of October 23, 2026 at 10:11 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $208M cash and investments vs $75M debt (Jun 2026, SEC), net cash |
| Cash Flow | Weak — FCF negative: -$86M (FY ended Dec 2025, 10-K), burning cash |
| Efficiency | Critical — ROE -113%, ROA -28.1% |
Ownership (XFOR)
| Insider Ownership | +0.45% |
|---|---|
| Institutional Ownership | +103.83% |
| Shares Outstanding | 99.15M |
| Float | 57.22M |
| Short % of Float | +7.67% |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Leadership (XFOR)
X4 Pharmaceuticals, Inc. is led by John P. Volpone, President & COO, per Nexqual as of October 23, 2026 at 10:11 UTC.
| President & COO | John P. Volpone |
|---|---|
| CFO, Treasurer & Corporate Secretary | David H. Kirske |
Major Backers & Investors (XFOR)
Notable institutional backers of X4 Pharmaceuticals, Inc. include Morgan Stanley, Fidelity, FMR, LLC, according to Nexqual as of October 23, 2026 at 10:11 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Morgan Stanley | 9.54% |
| Fidelity | 8.8% |
| FMR, LLC | 8.39% |
| Bain Capital Life Sciences Investors, LLC | 8.04% |
| Perceptive Advisors Llc | 8% |
| Saturn V Capital Management LP | 7.03% |
| Empery Asset Management, LP | 6.99% |
| Deep Track Capital, Lp | 5.93% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 5.6% |
| Vanguard Group | 3.75% |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 307.82 | ▼ 2.21% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 90.9 | ▲ 2.57% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.14 | ▼ 3.28% |
| PRAX | Praxis Precision Medicines, Inc | USD 258.92 | ▲ 0.96% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 43.91 | ▼ 0.81% |
| ABVX | Abivax SA | USD 90.23 | ▼ 3.49% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:11 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt